BCL-XL/BCL-2 co-dependent cell lines could be targeted with navitoclax, however, the clinical translation of navitoclax is hampered by dose-limiting on-target toxicity of thrombocytopenia [14, 15]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.